文献库搜索 | GeneLibs

Kantarjian(H),Shah(N P),Hochhaus(A),Cortes... J Clin Oncol 0000-00-00

...mos; median treatment duration was 14 mos. 85% of dasatinib and 81% of IM pts remained on study. Median dose intensity w...

Bergh(J),Greil(R),Voytko(N),Makhson(A),Cor... J Clin Oncol 0000-00-00

...mos (95% CI 8.2-10.3) in the SU+D arm vs 8.3 mos (95% CI 7.7-9.6) for the D arm (HR 0.922). Median OS was 24.8 mos (95% ...

Crown(J),Dieras(V),Staroslawska(E),Yardley... J Clin Oncol 0000-00-00

...mos (95% CI 4.5-6.0) in the SU+C arm vs. 5.9 mos (95% CI 5.4-7.6) in the C arm (HR 1.224). Median OS was 16.4 mos (95% C...

Gajjar(A J),Stewart(C F),Ellison(D W),Curr... J Clin Oncol 0000-00-00

...mos to assess abnormalities in bone development.,To date 11 eligible patients have been enrolled on the trial (10 males,...

Marten(A),Schmidt(J),Debus(J),Harig(S),Lin... J Clin Oncol 0000-00-00

...mOS) of 23 months. Phase II trials evaluating adjuvant CRI showed promising results (mOS 27-44 months).,Patients with an...

Goss(G D),Lorimer(I),Tsao(M S),O'Callaghan... J Clin Oncol 0000-00-00

...mos. For gefitinib versus placebo, median DFS is 4.2 yrs versus not yet reached (NYR) HR1.22 (95% C.I. 0.93-1.61), p=0.1...

Belani(C P),Brodowicz(T),Ciuleanu(T),Kim(J... J Clin Oncol 0000-00-00

...mos [HR 0.79, 95% CI: 0.65-0.95, P = 0.012]). As reported earlier, Pem also had better PFS (P <0.00001) and response (P ...

Miller(V A),O'Connor(P),Soh(C),Kabbinavar(F), J Clin Oncol 0000-00-00

...mos for (B + E) vs. 3.7 mos for (B + P), HR= 0.722 (95% CI: 0.592-0.881), p = 0.0012. The safety profile for B + E was c...

Inoue(Takayuki),Ito(Satoru),Ando(Masahiko)... BMC Sports Sci Med Rehabil 0000-00-00

...MOS 36-item Short-Form Health Survey (SF-36) Questionnaire for general health were assessed.,The mean age was 67.3 ± 8.1...

Ding(Xi),Qian(Ji),Yang(Yang),Xu(Wen),Liu(D... Am J Cancer Res 0000-00-00

...mOS vs AA genotype 14.2 months mOS (HR: 1.38, 95% CI: 1.11-1.72, p=0.004). In further analysis, rs949037 was found to pr...